BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22955431)

  • 21. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
    Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
    J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
    Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
    J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia.
    Brunet AS; Ploton C; Galambrun C; Pondarré C; Pages MP; Bleyzac N; Freydière AM; Barbé G; Bertrand Y
    Pediatr Blood Cancer; 2006 Nov; 47(6):765-72. PubMed ID: 16333838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasive Rothia infections in children with acute myeloid leukemia: A report from the Canadian infections in AML research group.
    Wang JY; Brossard J; Cellot S; Dix D; Feusner J; Johnston DL; Lewis V; Mitchell D; Portwine C; Price V; Sung L; Ethier MC; Gillmeister B
    Pediatr Hematol Oncol; 2016 Aug; 33(5):277-281. PubMed ID: 27315594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
    Sisler IY; Koehler E; Koyama T; Domm JA; Ryan R; Levine JE; Pulsipher MA; Haut PR; Schultz KR; Taylor DS; Frangoul HA
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
    Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
    Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma.
    Auner HW; Sill H; Mulabecirovic A; Linkesch W; Krause R
    Ann Hematol; 2002 Jul; 81(7):374-7. PubMed ID: 12185506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study.
    Castagnola E; Rossi MR; Cesaro S; Livadiotti S; Giacchino M; Zanazzo G; Fioredda F; Beretta C; Ciocchello F; Carli M; Putti MC; Pansini V; Berger M; Licciardello M; Farina S; Caviglia I; Haupt R
    Pediatr Blood Cancer; 2010 Dec; 55(6):1103-7. PubMed ID: 20680968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
    Gil L; Styczynski J; Komarnicki M
    Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia.
    Afzal S; Ethier MC; Dupuis LL; Tang L; Punnett AS; Richardson SE; Allen U; Abla O; Sung L
    Pediatr Infect Dis J; 2009 Dec; 28(12):1064-8. PubMed ID: 19773675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Acute myeloid leukemia].
    Tabuchi K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):156-61. PubMed ID: 17301520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
    Lübbert M; Bertz H; Wäsch R; Marks R; Rüter B; Claus R; Finke J
    Bone Marrow Transplant; 2010 Apr; 45(4):627-32. PubMed ID: 19718057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia.
    Felsenstein S; Orgel E; Rushing T; Fu C; Hoffman JA
    Pediatr Infect Dis J; 2015 Apr; 34(4):e78-84. PubMed ID: 25764103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
    Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR
    Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.